Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

non-small cell lung cancer

22nd Jan 2026

HARMONi-2 trial results comparing two treatments for PD-L1–positive non-small cell lung cancer: a plain language summary

28th Nov 2025

TROPION-Lung01 trial for non-small cell lung cancer treatment: a plain language summary

20th May 2025

Plain language summary: EVOKE-01 study comparing sacituzumab govitecan vs docetaxel for lung cancer

25th Apr 2025

Plain language summary of first-line treatment with amivantamab-lazertinib for high-risk EGFR-positive lung cancer from the MARIPOSA study

13th Mar 2025

Plain language summary of the FLAURA2 study: Impact of first-line osimertinib plus chemotherapy on brain health in patients with EGFR-mutated advanced non-small cell lung cancer

25th Feb 2025

A plain language summary of the FLAURA2 study results: First-line osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC

18th Oct 2024

5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer

25th Jul 2024

Plain Language Summary of amivantamab combined with chemotherapy in PAPILLON study for untreated EGFR-mutated non-small-cell lung cancer

This is a plain language summary of a clinical research study. The study waslooking the effects of a drug called anamorelin for Japanese people withadvanced non-small cell lung cancer (often shortened to NSCLC) who alsohad a condition called cachexia. People with cachexia have a loss of appetite,severe weight loss, loss of body fat and loss of muscle mass (called musclewasting). Cachexia is common in many chronic (long term) diseases, such ascancer and can lead to a decrease in a person's ability to do everyday tasks(called functional strength). Cachexia can negatively affect a person's qualityof life and increases the risk of serious side effects during chemotherapy.Anamorelin is a drug that has been shown in previous research studies to improve appetite and increase lean body mass(the total weight of the body, not counting fat) and overall body weight. In this study, participants were given anamorelin(100 mg daily) for 12 weeks.
26th Jun 2024

Anamorelin for the treatment of Japanese people with non-small cell lung cancer and cachexia: A plain language summary

This is a summary of the results of a study called PHAROS. This study looked at combination treatment with encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®). This combination of medicines was studied in people with metastatic non-small-cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. Metastatic means that the cancer has spread to other parts of the body. All people in this study had a type of NSCLC that has a change in a gene called BRAF termed a BRAF V600E mutation. A gene is a part of the DNA that has instructions for making things that your body needs to work, and the BRAF V600E mutation contributes to the growth of the lung cancer.
23rd Feb 2024

A plain language summary looking at the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

This is a summary of a research study called ARROW, which tested a medicine called pralsetinib in patients with non-small cell lung cancer (NSCLC), thyroid cancer, and other advanced solid tumours caused by a change in a gene called RET. For the purposes of this summary, only patients with NSCLC with a change in RET called fusion (RET fusion+) are highlighted
14th Nov 2023

A plain language summary of the ARROW study: pralsetinib in patients with RET fusion–positive non-small cell lung cancer

12th Apr 2023

Plain Language Summary: Afatinib for the treatment of non-small-cell lung cancer with unusual EGFR mutations

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy